MA
ALXN

Mutual Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Mutual Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,207
Closed -$222K – 914
2021
Q2 		$222K Buy
+1,207
New +$207K 0.01% 763
2021
Q1 		– Sell
-1,348
Closed -$211K – 840
2020
Q4 		$211K Buy
+1,348
New +$173K 0.02% 686

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Mutual Advisors's ALXN Position: Q3 2021 in Review

Mutual Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,207 shares — an estimated $222K sold.

Mutual Advisors first reported a position in ALXN in Q4 2020 and held it in 2 quarters. The position peaked at $222K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mutual Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mutual Advisors sold 1,207 Alexion Pharmaceuticals shares in Q3 2021, an estimated $222K.
  • Mutual Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Mutual Advisors's Alexion Pharmaceuticals position peaked at $222K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mutual Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.